Ropivacaine
- Generic Name
- Ropivacaine
- Brand Names
- Naropin
- Drug Type
- Small Molecule
- Chemical Formula
- C17H26N2O
- CAS Number
- 84057-95-4
- Unique Ingredient Identifier
- 7IO5LYA57N
- Background
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
- Indication
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
- Associated Conditions
- Acute Pain, Postoperative pain
- Associated Therapies
- Surgical anesthesia therapy
Exparel for Total Shoulder Pain
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 60
- Registration Number
- NCT03739021
Liposomal Bupivacaine in Rotator Cuff Repair
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 64
- Registration Number
- NCT03738696
- Locations
- 🇺🇸
UAB Hospital-Highlands, Birmingham, Alabama, United States
The Benefit of Local Anesthesia at the Sternum in Patients With Coronary Surgery
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- CMC Ambroise Paré
- Target Recruit Count
- 35
- Registration Number
- NCT03734159
- Locations
- 🇫🇷
CMC Ambroise Paré, Neuilly-sur-Seine, Ile-de-France, France
Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa
- Conditions
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 10
- Registration Number
- NCT03730584
- Locations
- 🇫🇷
Hôpital Necker Enfants Malades, Paris, France
Pharmacokinetic of Thoracic Paravertebral Ropivacaine
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Attikon Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03721406
- Locations
- 🇬🇷
2nd Department of Anesthesiology, Attikon University Hospital, Athens, Attiki, Greece
🇬🇷Paraskevi K Matsota, Athens, Other, Greece
New Truncal Nerve Blocks for Thoracoscopic Surgery and Open Heart Surgery.
- Conditions
- Interventions
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Tampere University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT03704753
- Locations
- 🇫🇮
Tampere Heart Hospital, Tampere, Finland
Ropivacaine For Post-POEM Pain Control
- Conditions
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Lawrence Charles Hookey
- Target Recruit Count
- 20
- Registration Number
- NCT03702647
- Locations
- 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
Comparison of TAP, Anterior QL, or ESP Block for Elective Cesarean Section
- Conditions
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Duke University
- Target Recruit Count
- 12
- Registration Number
- NCT03695172
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Erector Spinae Plane Block (ESPB): in Patients Undergoing Surgery Through a Flank or Anterior Subcostal Incision.
- Conditions
- Interventions
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT03691935
- Locations
- 🇺🇸
Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
Sphenopalatine Ganglion Blocks RCT
- Conditions
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 10
- Registration Number
- NCT03666663
- Locations
- 🇺🇸
UCSF Headache Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.